Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 185

1.

Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome.

Brito-Zerón P, Retamozo S, Kostov B, Baldini C, Bootsma H, De Vita S, Dörner T, Gottenberg JE, Kruize AA, Mandl T, Ng WF, Seror R, Tzioufas AG, Vitali C, Bowman S, Mariette X, Ramos-Casals M.

RMD Open. 2019 Oct 28;5(2):e001064. doi: 10.1136/rmdopen-2019-001064. eCollection 2019. Review.

2.

Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study.

Jaeger VK, Tikly M, Xu D, Siegert E, Hachulla E, Airò P, Valentini G, Matucci Cerinic M, Distler O, Cozzi F, Carreira P, Allanore Y, Müller-Ladner U, Ananieva LP, Balbir-Gurman A, Distler JHW, Czirják L, Li M, Henes J, Jimenez SA, Smith V, Damjanov N, Denton CP, DelGaldo F, Saketkoo LA, Walker UA; EUSTAR co-authors .

Rheumatology (Oxford). 2019 Nov 4. pii: kez486. doi: 10.1093/rheumatology/kez486. [Epub ahead of print]

PMID:
31680161
3.

EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies.

Ramos-Casals M, Brito-Zerón P, Bombardieri S, Bootsma H, De Vita S, Dörner T, Fisher BA, Gottenberg JE, Hernandez-Molina G, Kocher A, Kostov B, Kruize AA, Mandl T, Ng WF, Retamozo S, Seror R, Shoenfeld Y, Sisó-Almirall A, Tzioufas AG, Vitali C, Bowman S, Mariette X; EULAR-Sjögren Syndrome Task Force Group.

Ann Rheum Dis. 2019 Oct 31. pii: annrheumdis-2019-216114. doi: 10.1136/annrheumdis-2019-216114. [Epub ahead of print]

PMID:
31672775
4.

Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR).

Ramos-Casals M, Maria A, Suárez-Almazor ME, Lambotte O, Fisher BA, Hernández-Molina G, Guilpain P, Pundole X, Flores-Chávez A, Baldini C, Bingham Iii CO, Brito-Zerón P, Gottenberg JE, Kostine M, Radstake TRD, Schaeverbeke T, Schulze-Koops H, Calabrese L, Khamashta MA, Mariette X; ICIR.

Clin Exp Rheumatol. 2019 May-Jun;37 Suppl 118(3):114-122. Epub 2019 Aug 28.

5.

Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis.

Virone A, Bastard JP, Fellahi S, Capeau J, Rouanet S, Sibilia J, Ravaud P, Berenbaum F, Gottenberg JE, Sellam J.

RMD Open. 2019 Jul 21;5(2):e000897. doi: 10.1136/rmdopen-2019-000897. eCollection 2019.

6.

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.

Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy JS, de Vlam K, Walker D, Takeuchi T.

JAMA. 2019 Jul 23;322(4):315-325. doi: 10.1001/jama.2019.9055.

PMID:
31334793
7.

Serum level of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) is a biomarker of synovitis in rheumatoid arthritis.

Gorlier C, Gottenberg JE, Laurans L, Simon T, Ait-Oufella H, Sellam J.

Int J Rheum Dis. 2019 Sep;22(9):1616-1618. doi: 10.1111/1756-185X.13656. Epub 2019 Jul 16. No abstract available.

PMID:
31309716
8.

T1 mapping cardiac magnetic resonance imaging frequently detects subclinical diffuse myocardial fibrosis in systemic sclerosis patients.

Poindron V, Chatelus E, Canuet M, Gottenberg JE, Arnaud L, Gangi A, Gavand PE, Guffroy A, Korganow AS, Germain P, Sibilia J, El Ghannudi S, Martin T.

Semin Arthritis Rheum. 2019 Jun 19. pii: S0049-0172(18)30711-X. doi: 10.1016/j.semarthrit.2019.06.013. [Epub ahead of print]

9.

Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren's syndrome in the JOQUER randomized trial.

Bodewes ILA, Gottenberg JE, van Helden-Meeuwsen CG, Mariette X, Versnel MA.

Rheumatology (Oxford). 2019 Jun 25. pii: kez242. doi: 10.1093/rheumatology/kez242. [Epub ahead of print]

PMID:
31237947
10.

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis.

Becker M, Graf N, Sauter R, Allanore Y, Curram J, Denton CP, Khanna D, Matucci-Cerinic M, de Oliveira Pena J, Pope JE, Distler O; EUSTAR Collaborators; EUSTAR Collaborators (numerical order of centres).

Ann Rheum Dis. 2019 Sep;78(9):1242-1248. doi: 10.1136/annrheumdis-2019-215145. Epub 2019 Jun 21.

11.

Discrepancy of Serological and Molecular Patterns of Circulating Epstein-Barr Virus Reactivation in Primary Sjögren's Syndrome.

Sanosyan A, Daien C, Nutz A, Bollore K, Bedin AS, Morel J, Zimmermann V, Nocturne G, Peries M, Guigue N, Gottenberg JE, Van de Perre P, Mariette X, Tuaillon E.

Front Immunol. 2019 May 29;10:1153. doi: 10.3389/fimmu.2019.01153. eCollection 2019.

12.

Treatment of Sjögren's syndrome: current therapy and future directions.

Fox RI, Fox CM, Gottenberg JE, Dörner T.

Rheumatology (Oxford). 2019 Apr 26. pii: kez142. doi: 10.1093/rheumatology/kez142. [Epub ahead of print]

PMID:
31034046
13.

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis.

Sobanski V, Giovannelli J, Allanore Y, Riemekasten G, Airò P, Vettori S, Cozzi F, Distler O, Matucci-Cerinic M, Denton C, Launay D, Hachulla E; EUSTAR Collaborators.

Arthritis Rheumatol. 2019 Sep;71(9):1553-1570. doi: 10.1002/art.40906. Epub 2019 Aug 12.

14.

Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.

Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellví I, Airó P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y; for EUSTAR network.

Ann Rheum Dis. 2019 Jul;78(7):979-987. doi: 10.1136/annrheumdis-2018-214816. Epub 2019 Apr 9.

PMID:
30967395
15.

The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials.

Felten R, Scher F, Sibilia J, Gottenberg JE, Arnaud L.

Autoimmun Rev. 2019 Jun;18(6):576-582. doi: 10.1016/j.autrev.2018.12.008. Epub 2019 Apr 6.

PMID:
30959220
16.

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.

Wu W, Jordan S, Graf N, de Oliveira Pena J, Curram J, Allanore Y, Matucci-Cerinic M, Pope JE, Denton CP, Khanna D, Distler O; EUSTAR Collaborators.

Ann Rheum Dis. 2019 May;78(5):648-656. doi: 10.1136/annrheumdis-2018-213455. Epub 2019 Mar 9.

17.

Muscle fluorodeoxyglucose uptake assessed by positron emission tomography-computed tomography as a biomarker of inflammatory myopathies disease activity.

Matuszak J, Blondet C, Hubelé F, Gottenberg JE, Sibilia J, Bund C, Geny B, Namer IJ, Meyer A.

Rheumatology (Oxford). 2019 Mar 8. pii: kez040. doi: 10.1093/rheumatology/kez040. [Epub ahead of print]

PMID:
30851092
18.

The classical NLRP3 inflammasome controls FADD unconventional secretion through microvesicle shedding.

Mouasni S, Gonzalez V, Schmitt A, Bennana E, Guillonneau F, Mistou S, Avouac J, Ea HK, Devauchelle V, Gottenberg JE, Chiocchia G, Tourneur L.

Cell Death Dis. 2019 Feb 25;10(3):190. doi: 10.1038/s41419-019-1412-9.

19.

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.

Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, Flipo RM, Saraux A, Schaeverbeke T, Sibilia J, Soubrier M, Vittecoq O, Baron G, Constantin A, Ravaud P, Mariette X; French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries.

BMJ. 2019 Jan 24;364:l67. doi: 10.1136/bmj.l67.

20.

Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?

Kostine M, Cappelli LC, Calabrese C, Calabrese LH, Bingham CO 3rd, Richez C, Gottenberg JE, Lambotte O.

Ann Rheum Dis. 2019 Jun;78(6):860-862. doi: 10.1136/annrheumdis-2018-214748. Epub 2019 Jan 18. No abstract available.

PMID:
30659050

Supplemental Content

Loading ...
Support Center